 |
|
|
| |
Retrospective Comparison of Etravirine and Darunavir/Ritonavir as Dual Therapy in Early Treatment-Experienced Subjects (INROADS) to a Matched Historical Control Cohort
|
| |
| |
INROADS was a Phase 2b, single-arm, open-label, multicenter, 48-week US trial that evaluated ETR 400mg (two 200mg tablets) and DRV/r 800/100mg (two 400mg tablets DRV, 1 tablet ritonavir), all qd, in HIV-1-infected, ARV treatment-experienced adults sensitive to DRV and ETR, or in treatment-naïve adults who were infected with a strain of HIV-1 already resistant to 1 or more drugs (transmitted resistance)
"Overall efficacy (HIV-1 RNA <50 copies/mL) was 87% (32/37) (CVR, non-VF censored at Week 48; primary end point).......Black subjects in INROADS achieved CVR (<50 HIV-1 RNA copies/mL) at Week 48 (96%, 21/22)"
Reported by Jules Levin
14th European AIDS Conference (EACS), Brussels, Belgium, October 16-19, 2013.
Peter Ruane,1 Javier Morales-Ramirez,2 Harold Katner,3 Chiu-Bin Hsiao,4 Bruce Coate,5 Robert Ryan,5 Michelle Cho,6 David Anderson6
1Peter J. Ruane MD Inc, Los Angeles, California, USA; 2Clinical Research Puerto Rico Inc., San Juan, Puerto Rico; 3Mercer University School of Medicine, Department of Internal Medicine, Macon, Georgia, USA; 4The Positive Health Clinic, Allegheny General Hospital,
Pittsburgh, Pennsylvania, USA; 5Janssen Research & Development, Titusville, New Jersey, USA; 6Janssen Services, LLC, Titusville, New Jersey, USA
|
| |
|
|
|
|
|
